Overview
FARMAKEIO Pharmacy Network provides patient-specific medications through custom compounding, outsourcing, and retail pharmacy services, delivering sterile and non-sterile formulations for hormone therapy, weight loss, cognitive function, and sexual health. Its FDA-registered 503B facility produces a patented bioidentical hormone pellet designed for consistent dosing and better absorption. The company stands out by offering a nationwide, vertically integrated model that combines outsourcing, compounding, and retail services under family leadership, with free standard shipping to most US states and territories. Its goal is to ensure high-quality, customized medicines and reliable delivery for patients and clinicians while expanding production capacity.
Work here?Claim your company
Simplify's take
What believers are saying
- FDA restored access to six peptides on October 28, 2026, reviving demand.
- Open October 2026 technician and compliance roles signal active volume growth.
- Free shipping and cold-chain fulfillment support national provider adoption.
What critics are saying
- Ohio suspended FarmaKeio on September 8, 2026 for 13,070 improper prescriptions.
- FDA cited 2025 sterile-compounding failures, including chipped paint near ISO 5 hoods.
- Repeated FDA and Ohio actions threaten licenses, payer relationships, and patient trust.
What makes FARMAKEIO Pharmacy Network unique
- Dan DeNeui built a 503A and 503B network spanning 49 states, Puerto Rico.
- FarmaKeio offers patient-specific sterile, non-sterile, and peptide compounding plus retail pharmacy services.
- Its 2023 Conway expansion added 16,000 square feet and 74 planned jobs.
Help us improve and share your feedback! Did you find this helpful?